Peuget S, Zhou X, Selivanova G
Nat Rev Cancer. 2024; 24(3):192-215.
PMID: 38287107
DOI: 10.1038/s41568-023-00658-3.
Guo X, Zhang Y, Li Q, Shi F, HuangFu Y, Li J
Apoptosis. 2023; 29(5-6):865-881.
PMID: 38145442
DOI: 10.1007/s10495-023-01926-1.
Li J, Guo M, Chen L, Chen Z, Fu Y, Chen Y
Exp Hematol Oncol. 2022; 11(1):66.
PMID: 36171607
PMC: 9520902.
DOI: 10.1186/s40164-022-00317-7.
Szudy-Szczyrek A, Ahern S, Krawczyk J, Szczyrek M, Hus M
J Pers Med. 2022; 12(9).
PMID: 36143213
PMC: 9503263.
DOI: 10.3390/jpm12091428.
Li J, Peng L, Chen Q, Ye Z, Zhao T, Hou S
Cancers (Basel). 2022; 14(14).
PMID: 35884437
PMC: 9318555.
DOI: 10.3390/cancers14143377.
Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.
Zhan Y, Zhou X, Peuget S, Singh M, Peyser B, Fan Z
Mol Cancer Ther. 2022; 21(10):1524-1534.
PMID: 35877475
PMC: 9538593.
DOI: 10.1158/1535-7163.MCT-22-0119.
Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells.
Gomes D, Yaduvanshi S, Silvestre S, Duarte A, Santos A, Soares C
Cancers (Basel). 2022; 14(12).
PMID: 35740499
PMC: 9221127.
DOI: 10.3390/cancers14122834.
p53-Dependent Repression: DREAM or Reality?.
Peuget S, Selivanova G
Cancers (Basel). 2021; 13(19).
PMID: 34638334
PMC: 8508069.
DOI: 10.3390/cancers13194850.
Structural and Drug Targeting Insights on Mutant p53.
Gomes A, Ramos H, Inga A, Sousa E, Saraiva L
Cancers (Basel). 2021; 13(13).
PMID: 34283062
PMC: 8268744.
DOI: 10.3390/cancers13133344.
Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro.
Li J, Zeng T, Tang S, Zhong M, Huang Q, Li X
Clin Transl Oncol. 2021; 23(9):1847-1856.
PMID: 33821368
DOI: 10.1007/s12094-021-02594-w.
Antitumor Effects of PRIMA-1 and PRIMA-1 (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?.
Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F
Cells. 2021; 10(1).
PMID: 33430525
PMC: 7827888.
DOI: 10.3390/cells10010098.
Heterogeneity of Mutations and P53 Protein Residual Function in Cancer: Does It Matter?.
Monti P, Menichini P, Speciale A, Cutrona G, Fais F, Taiana E
Front Oncol. 2020; 10:593383.
PMID: 33194757
PMC: 7655923.
DOI: 10.3389/fonc.2020.593383.
Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.
Soliman A, Lin T, Mahakkanukrauh P, Das S
Int J Mol Sci. 2020; 21(20).
PMID: 33066062
PMC: 7589124.
DOI: 10.3390/ijms21207539.
Identification and targeting of selective vulnerability rendered by tamoxifen resistance.
Singh M, Zhou X, Chen X, Santos G, Peuget S, Cheng Q
Breast Cancer Res. 2020; 22(1):80.
PMID: 32727562
PMC: 7388523.
DOI: 10.1186/s13058-020-01315-5.
Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells.
Pu Q, Lv Y, Dong K, Geng W, Gao H
BMC Cancer. 2020; 20(1):583.
PMID: 32571254
PMC: 7310228.
DOI: 10.1186/s12885-020-07069-9.
Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
Silva J, Lima C, Rangel L, Ferretti G, Pauli F, Ribeiro R
Biomolecules. 2020; 10(4).
PMID: 32326087
PMC: 7226499.
DOI: 10.3390/biom10040635.
Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30.
Rizzotto D, Zaccara S, Rossi A, Galbraith M, Andrysik Z, Pandey A
Cell Rep. 2020; 30(13):4355-4369.e6.
PMID: 32234473
PMC: 7182397.
DOI: 10.1016/j.celrep.2020.03.011.
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Li Z, Zhang Y, Wang R, Zou K, Zou L
Exp Ther Med. 2019; 18(4):2369-2377.
PMID: 31555347
PMC: 6755274.
DOI: 10.3892/etm.2019.7869.
Inhibition of p53 inhibitors: progress, challenges and perspectives.
Sanz G, Singh M, Peuget S, Selivanova G
J Mol Cell Biol. 2019; 11(7):586-599.
PMID: 31310659
PMC: 6735775.
DOI: 10.1093/jmcb/mjz075.
An evaluation of the efficacy of nutlin-3 and topotecan in combination with Lu-DOTATATE for the treatment of neuroblastoma.
Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M
Oncotarget. 2018; 9(49):29082-29096.
PMID: 30018737
PMC: 6044389.
DOI: 10.18632/oncotarget.25607.